View Older Stories View More Recent Stories

Feb 5, 2026 06:42AM H.C. Wainwright Starts Incyte (INCY) at Buy
Jan 30, 2026 09:29AM Incyte gets positive CHMP opinion for anal cancer drug Zynyz
Jan 20, 2026 05:36AM Wells Fargo Downgrades Incyte (INCY) to Equal Weight
Jan 13, 2026 08:50AM Incyte (INCY) PT Raised to $128 at TD Cowen
Jan 5, 2026 01:33PM Stifel Reiterates Buy Rating on Incyte (INCY)
Jan 5, 2026 12:10PM Incyte (INCY) PT Raised to $129 at Leerink Partners
Jan 5, 2026 07:30AM Incyte drug trial meets primary endpoint for lymphoma treatment
Dec 22, 2025 05:40AM Japan approves Incyte's Minjuvi for follicular lymphoma treatment
Dec 17, 2025 11:20AM INCYTE wins European approval for Minjuvi cancer treatment
Dec 11, 2025 05:59AM RBC Capital Reiterates Sector Perform Rating on Incyte (INCY)
Dec 9, 2025 05:12AM Incyte's (INCY) 989 is First-in-Class, Has Broad Clinical Utility - Citizens
Dec 8, 2025 04:30PM Incyte presents data showing 90% response rate for blood cancer drug
Dec 8, 2025 06:20AM Incyte (INCY) PT Raised to $128 at Leerink Partners
Dec 8, 2025 05:18AM Incyte (INCY) PT Raised to $118 at BofA Securities
Dec 8, 2025 04:53AM Mizuho Upgrades Incyte (INCY) to Outperform 'on Higher Confidence in Pipeline'
Dec 8, 2025 02:53AM FDA grants breakthrough therapy designation to INCA033989 for blood cancer
Dec 8, 2025 02:53AM Incyte reports phase 1 data for myelofibrosis drug INCA033989
Nov 17, 2025 03:57AM CHMP recommends Incyte's Minjuvi for relapsed follicular lymphoma
Nov 16, 2025 03:00PM Where can biotech stocks go from here? RBC answers
Nov 4, 2025 07:01AM Prelude Therapeutics secures $60M from Incyte option deal
Oct 29, 2025 09:59AM Incyte (INCY) PT Raised to $101 at TD Cowen; 'Q3 Beats Across All Franchises'
Oct 28, 2025 03:29PM Incyte (INCY) PT Raised to $84 at Oppenheimer
Oct 28, 2025 10:31AM Incyte (INCY) PT Raised to $109 at BofA Securities
Oct 28, 2025 07:02AM Incyte (INCY) Tops Q3 EPS by 67c; raises guidance
Oct 14, 2025 09:46AM Incyte (INCY) PT Raised to $76 at UBS
Oct 8, 2025 02:56AM Oppenheimer Downgrades Incyte (INCY) to Perform
Oct 3, 2025 04:03PM Incyte appoints Thomas Tray as principal financial officer
Sep 24, 2025 05:03AM Incyte (INCY) PT Raised to $81 at RBC Capital
Sep 22, 2025 04:39AM Incyte (INCY) PT Raised to $115 at Stifel
Sep 18, 2025 04:15AM Citizens JMP Reiterates Market Perform Rating on Incyte (INCY)
Sep 3, 2025 09:15AM Incyte launches awareness campaign for hidradenitis suppurativa patients
Aug 1, 2025 03:59AM Barclays Starts Incyte (INCY) at Overweight
Jul 30, 2025 08:29AM Incyte (INCY) PT Raised to $60 at BMO Capital
Jul 30, 2025 07:59AM Incyte (INCY) PT Raised to $72 at RBC Capital
Jul 29, 2025 04:12PM Incyte (INCY) PT Raised to $79 at Truist Securities
Jul 29, 2025 04:06PM Incyte (INCY) PT Raised to $89 at TD Cowen
Jul 29, 2025 07:02AM Incyte (INCY) Misses Q2 EPS by 140c
Jul 24, 2025 05:02PM Incyte to present cancer drug data at ESMO Congress 2025
Jul 15, 2025 09:44AM Incyte (INCY) PT Raised to $62 at UBS
Jun 26, 2025 12:27PM William Blair Comments on Incyte (INCY) CEO Transition
Jun 26, 2025 10:36AM Citi Comments Incyte (INCY) New CEO
Jun 26, 2025 09:45AM Incyte (INCY) new CEO sparks chatter
Jun 26, 2025 09:18AM Incyte (INCY) CEO change timing 'feels right' - Stifel
Jun 26, 2025 07:30AM Incyte (INCY) Appoints Bill Meury as Next CEO
Jun 20, 2025 04:31PM Incyte (INCY) announces that FDA extends review for Ruxolitinib cream
Jun 18, 2025 03:39PM Incyte (INCY) Announces FDA Approval of Monjuvi in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
Jun 18, 2025 03:38PM FDA approves Incyte's tafasitamab-cxix for relapsed or refractory follicular lymphoma
Jun 16, 2025 07:55AM Incyte (INCY): Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
Jun 16, 2025 06:11AM Oppenheimer Reiterates Outperform Rating on Incyte (INCY)
Jun 16, 2025 04:48AM Incyte (INCY) PT Raised to $82 at Jefferies
View More Recent Stories View Older Stories